BACKGROUND: The International Neuroblastoma Pathology Classification (INPC) was the first to clearly define prognostic subgroups in ganglioneuroma (GN) and ganglioneuroblastoma (GNB). PROCEDURE: Histopathology and tumor resectability of 552 GN/GNB cases from the Children's Cancer Group (CCG) and Children's Oncology Group (COG) neuroblastoma studies were reviewed. The results were analyzed along with clinical information and biological data of the cases. RESULTS: According to the INPC, 300 tumors were classified into the Favorable Histology (FH) group and 252 were into the Unfavorable Histology (UH) group. Tumors in the FH group included 43 ganglioneuroma-maturing (GN-M), 198 ganglioneuroblastoma-intermixed (GNB-I), and 59 ganglioneuroblastoma-nodular, favorable subset (GNB-N-FS), and were often (91%) resected completely by single or multiple surgical procedures. Patients with the FH tumors had an excellent prognosis with no tumor-related deaths. The UH group included ganglioneuroblastoma-nodular, unfavorable subset (GNB-N-US) tumors. Patients with the UH tumors had a high incidence (53%) of distant metastasis at the time of diagnosis, and their prognosis significantly depended on clinical stage (5-year EFS: 80.1% for non-stage 4 patients; 16.7% for stage 4 patients): Complete primary tumor resection was not beneficial to those GNB-N-US patients, regardless of whether metastasis was present or not. MYCN amplification was detected in four tumors in the FH group and six tumors in the UH group. The majority (160/191, 84%) of GN-M and GNB-I tumors had a diploid pattern determined by flow cytometry. CONCLUSIONS: Stringent application of the INPC along with clinical staging was critical for prognostic evaluation of the patients with this group of tumors.
BACKGROUND: The International Neuroblastoma Pathology Classification (INPC) was the first to clearly define prognostic subgroups in ganglioneuroma (GN) and ganglioneuroblastoma (GNB). PROCEDURE: Histopathology and tumor resectability of 552 GN/GNB cases from the Children's Cancer Group (CCG) and Children's Oncology Group (COG) neuroblastoma studies were reviewed. The results were analyzed along with clinical information and biological data of the cases. RESULTS: According to the INPC, 300 tumors were classified into the Favorable Histology (FH) group and 252 were into the Unfavorable Histology (UH) group. Tumors in the FH group included 43 ganglioneuroma-maturing (GN-M), 198 ganglioneuroblastoma-intermixed (GNB-I), and 59 ganglioneuroblastoma-nodular, favorable subset (GNB-N-FS), and were often (91%) resected completely by single or multiple surgical procedures. Patients with the FH tumors had an excellent prognosis with no tumor-related deaths. The UH group included ganglioneuroblastoma-nodular, unfavorable subset (GNB-N-US) tumors. Patients with the UH tumors had a high incidence (53%) of distant metastasis at the time of diagnosis, and their prognosis significantly depended on clinical stage (5-year EFS: 80.1% for non-stage 4 patients; 16.7% for stage 4 patients): Complete primary tumor resection was not beneficial to those GNB-N-US patients, regardless of whether metastasis was present or not. MYCN amplification was detected in four tumors in the FH group and six tumors in the UH group. The majority (160/191, 84%) of GN-M and GNB-I tumors had a diploid pattern determined by flow cytometry. CONCLUSIONS: Stringent application of the INPC along with clinical staging was critical for prognostic evaluation of the patients with this group of tumors.
Authors: C A Perez; K K Matthay; J B Atkinson; R C Seeger; H Shimada; G M Haase; D O Stram; R B Gerbing; J N Lukens Journal: J Clin Oncol Date: 2000-01 Impact factor: 44.544
Authors: S Goto; S Umehara; R B Gerbing; D O Stram; G M Brodeur; R C Seeger; J N Lukens; K K Matthay; H Shimada Journal: Cancer Date: 2001-11-15 Impact factor: 6.860
Authors: H Shimada; J Chatten; W A Newton; N Sachs; A B Hamoudi; T Chiba; H B Marsden; K Misugi Journal: J Natl Cancer Inst Date: 1984-08 Impact factor: 13.506
Authors: Michel Peuchmaur; Emanuele S G d'Amore; Vijay V Joshi; Jun-ichi Hata; Borghild Roald; Louis P Dehner; Robert B Gerbing; Daniel O Stram; John N Lukens; Katherine K Matthay; Hiroyuki Shimada Journal: Cancer Date: 2003-11-15 Impact factor: 6.860
Authors: R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith Journal: Br J Cancer Date: 1977-01 Impact factor: 7.640
Authors: Rie Suganuma; Larry L Wang; Hideki Sano; Arlene Naranjo; Wendy B London; Robert C Seeger; Michael D Hogarty; Julie M Gastier-Foster; A Thomas Look; Julie R Park; John M Maris; Susan L Cohn; Gabriele Amann; Klaus Beiske; Catherine J Cullinane; Emanuele S G d'Amore; Claudio Gambini; Jason A Jarzembowski; Vijay V Joshi; Samuel Navarro; Michel Peuchmaur; Hiroyuki Shimada Journal: Pediatr Blood Cancer Date: 2012-06-28 Impact factor: 3.167
Authors: Sarah W DeParis; Michele Bloomer; Ying Han; M Reza Vagefi; Joseph T C Shieh; David A Solomon; James Grenert; Alejandra G de Alba Campomanes Journal: Ocul Oncol Pathol Date: 2016-11-22
Authors: Jacqueline Schaefers; Dirk Vervloessem; Dominique De Roover; Mania De Praeter; Jutte van der Werff Ten Bosch; Machiel van den Akker Journal: Clin Case Rep Date: 2016-05-26
Authors: Boris Decarolis; Thorsten Simon; Barbara Krug; Ivo Leuschner; Christian Vokuhl; Peter Kaatsch; Dietrich von Schweinitz; Thomas Klingebiel; Ingo Mueller; Lothar Schweigerer; Frank Berthold; Barbara Hero Journal: BMC Cancer Date: 2016-07-27 Impact factor: 4.430